Korro Bio (KRRO) Net Shares Issued and Repurchased (2018 - 2023)
Korro Bio's (KRRO) quarterly Net Shares Issued and Repurchased came in at $819050.0 in Q1 2023, up 225.44% on a YoY basis from $251677.0 in Q1 2022, and down 36.95% quarter-over-quarter from $1.3 million in Q4 2022.
Analysis
Korro Bio (KRRO) Net Shares Issued and Repurchased (2018 - 2023) Analysis & Trends
Korro Bio (KRRO) has reported Net Shares Issued and Repurchased for 6 consecutive years, with $819050.0 the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Net Shares Issued and Repurchased rose 225.44% year-over-year to $819050.0; the trailing twelve-month figure through Mar 2023 stood at $819050.0 (up 225.44% YoY), and the FY2022 full-year result was $1.3 million, down 4.3% from the prior year.
- Net Shares Issued and Repurchased fell to $819050.0 in Q1 2023 per KRRO's latest filing, from $1.3 million in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $3.0 million in Q4 2019 and bottomed at $251677.0 in Q1 2022.
- Historically, Net Shares Issued and Repurchased has averaged $1.3 million across 5 years, with a median of $1.2 million in 2021.
- The sharpest annual moves came in 2022 and 2023: Net Shares Issued and Repurchased slumped 77.9% in 2022, then surged 225.44% in 2023.
- Over 5 years, Net Shares Issued and Repurchased stood at $3.0 million in 2019, then slumped by 45.42% to $1.6 million in 2020, then fell by 17.52% to $1.4 million in 2021, then fell by 4.3% to $1.3 million in 2022, then plunged by 36.95% to $819050.0 in 2023.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $819050.0, $1.3 million, and $251677.0 for Q1 2023, Q4 2022, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | - |
| 10 | Korro Bio | 227.98 Mn | 112.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 819,050.00 |
| Dec 31, 2022 | 1.30 Mn |
| Mar 31, 2022 | 251,677.00 |
| Dec 31, 2021 | 1.36 Mn |
| Mar 31, 2021 | 1.14 Mn |
| Dec 31, 2020 | 1.65 Mn |
| Mar 31, 2020 | 1.11 Mn |
| Dec 31, 2019 | 3.02 Mn |
| Dec 31, 2018 | 1.44 Mn |